Skip to main content
How can employers build an effective GLP-1 employee benefits strategy? Insights from MAXIS claims data
By Dr Leena Johns, MAXIS GBN Chief Health & Wellness Officer

For decades, obesity was viewed largely through the lens of lifestyle, personal responsibility and behaviour rather than as a chronic disease requiring medical treatment. That legacy still shapes insurance design today.

The American Medical Association only formally recognised obesity as a disease in 2013, and in 2025, Italy became the first country to recognise it as a progressive, relapsing disease through national legislation.1,2

Clinical understanding has therefore moved faster than reimbursement architecture. Many employer health plans continue to restrict obesity treatment while routinely covering its downstream consequences, including diabetes, cardiovascular disease and musculoskeletal conditions.

Against this backdrop, GLP-1 therapies are not simply another pharmaceutical launch. They are changing how healthcare systems, insurers and employers think about obesity, diabetes and cardiometabolic risk; and they are likely to affect a growing range of benefits over time.

The clinical opportunity is meaningful, but the financial outcome is not predetermined. MAXIS data* shows encouraging reductions in selected cardiometabolic and procedural categories alongside greater increases in mental health, musculoskeletal and gastrointestinal spending.3

Source: MAXIS GBN data (September 2026)*

*Note on MAXIS Claims Data

MAXIS medical claims data comprises private medical claims paid by our network of insurers for multinational clients. The dataset covers 52 insurance partners in 36 countries, more than 7.9 million insured lives, over 1.5 million unique claimants and approximately 50 million claims records.

All data included in this whitepaper is derived from MAXIS medical claims data unless referenced otherwise.

The countries included in our claims data analysis are: Antigua and Barbuda, Bahrain, Belgium, Canada, Chile, Colombia, Costa Rica, Cyprus, Ecuador, Egypt, El Salvador, Greece, Guatemala, Honduras, Peru, Hong Kong, Indonesia, Jordan, Kuwait, Lebanon, Malaysia, Mexico, Nicaragua, Oman, Pakistan, Panama, Philippines, Qatar, Singapore, Spain, Taiwan, Thailand, Trinidad and Tobago, the United Arab Emirates (UAE), United Kingdom (UK) and Vietnam.

For more information about our data, refer to the about our data section of our 2026 whitepaper (see download link above), How can employers build an effective GLP-1 employee benefits strategy? Insights from MAXIS claims data.

References

  1. Kyle, T.K. and Dhurandhar, E.J., et al. (September 1, 2017) Regarding Obesity as a Disease: Evolving Policies and Their Implications. Endocrinology and Metabolism Clinics of North America. 45(3) https://pmc.ncbi.nlm.nih.gov/articles/PMC4988332/ (Sourced: August 2026)
  2. Malavazos, A.E. and Dubini, C., et al. (June 8, 2026) Italy passes obesity law: an opportunity to prevent cardiovascular disease across Europe. European Heart Journal – Quality of Care and Clinical Outcomes. 13(12)https://academic.oup.com/ehjqcco/advance-article/doi/10.1093/ehjqcco/qcag094/8704145 (Sourced: August 2026)
  3. Johns, L. MAXIS GBN (September 2026) How can employers build an effective GLP-1 employee benefits strategy? Insights from MAXIS claims data https://maxis-gbn.com/knowledge-centre/whitepapers/glp-1/ (Sourced: September 2026)